Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DR26FKJG3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,932
Award facts
- Contract value 100% obligated
- $1,931.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $1,931.83 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL auto-injector medication. This delivery order, issued on October 31, 2025, with an ultimate completion date of November 3, 2025, carries no set-aside designation and was awarded competitively. The order falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, demonstrating substantial contracting activity with the DLA's Medical Supply Chain division. The company's comprehensive product portfolio spans branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, positioning it to support the diverse medical supply requirements of military healthcare operations globally. The company's single-award IDC under PPV-G GEN V, valued at $499,999,999 with completion through December 31, 2036, authorizes the DLA to issue delivery orders for recurring pharmaceutical needs across its worldwide network of military medical facilities.
Quick answers
Who was awarded contract SPE2DR26FKJG3?
SPE2DR26FKJG3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 31, 2025.
How much is contract SPE2DR26FKJG3 worth?
The government has obligated $1,932 on SPE2DR26FKJG3.
Is contract SPE2DR26FKJG3 an order under another contract?
Yes. SPE2DR26FKJG3 is a delivery order under SPE2DR25D9105, an indefinite delivery contract.
Was contract SPE2DR26FKJG3 competed?
The extent of competition for SPE2DR26FKJG3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award